These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 16084533)
21. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. Witko-Sarsat V; Friedlander M; Nguyen Khoa T; Capeillère-Blandin C; Nguyen AT; Canteloup S; Dayer JM; Jungers P; Drüeke T; Descamps-Latscha B J Immunol; 1998 Sep; 161(5):2524-32. PubMed ID: 9725252 [TBL] [Abstract][Full Text] [Related]
22. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Rojas A; Morales MA Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904 [TBL] [Abstract][Full Text] [Related]
23. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Yan SF; D'Agati V; Schmidt AM; Ramasamy R Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228 [TBL] [Abstract][Full Text] [Related]
25. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Miyata T; van Ypersele de Strihou C; Kurokawa K; Baynes JW Kidney Int; 1999 Feb; 55(2):389-99. PubMed ID: 9987064 [TBL] [Abstract][Full Text] [Related]
26. Inflammation and oxidative stress in end-stage renal disease. Kaysen GA Adv Nephrol Necker Hosp; 2000; 30():201-14. PubMed ID: 11068643 [No Abstract] [Full Text] [Related]
27. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Miyata T; van Ypersele de Strihou C; Imasawa T; Yoshino A; Ueda Y; Ogura H; Kominami K; Onogi H; Inagi R; Nangaku M; Kurokawa K Kidney Int; 2001 Dec; 60(6):2351-9. PubMed ID: 11737610 [TBL] [Abstract][Full Text] [Related]
28. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797 [TBL] [Abstract][Full Text] [Related]
29. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders. Yamagishi S; Nakamura K; Takeuchi M Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119 [TBL] [Abstract][Full Text] [Related]
30. Advanced glycation end products: sparking the development of diabetic vascular injury. Goldin A; Beckman JA; Schmidt AM; Creager MA Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049 [TBL] [Abstract][Full Text] [Related]
31. [New markers of advanced damage caused by oxidative and carbonyl stress]. Kalousová M; Zima T; Tesar V; Stípek S Sb Lek; 2001; 102(4):465-72. PubMed ID: 12448197 [TBL] [Abstract][Full Text] [Related]
32. Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kalousová M; Zima T; Tesar V; Sulková S; Fialová L Kidney Int Suppl; 2003 May; (84):S62-4. PubMed ID: 12694311 [TBL] [Abstract][Full Text] [Related]
33. Advanced glycation end products: a possible link to angiotensin in an animal model. Bohlender J; Franke S; Sommer M; Stein G Ann N Y Acad Sci; 2005 Jun; 1043():681-4. PubMed ID: 16037293 [TBL] [Abstract][Full Text] [Related]
34. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Matsumoto S; Yoshida T; Murata H; Harada S; Fujita N; Nakamura S; Yamamoto Y; Watanabe T; Yonekura H; Yamamoto H; Ohkubo T; Kobayashi Y Biochemistry; 2008 Nov; 47(47):12299-311. PubMed ID: 19032093 [TBL] [Abstract][Full Text] [Related]
35. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Saito A; Takeda T; Sato K; Hama H; Tanuma A; Kaseda R; Suzuki Y; Gejyo F Ann N Y Acad Sci; 2005 Jun; 1043():637-43. PubMed ID: 16037287 [TBL] [Abstract][Full Text] [Related]
36. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. Takahashi HK; Mori S; Wake H; Liu K; Yoshino T; Ohashi K; Tanaka N; Shikata K; Makino H; Nishibori M J Pharmacol Exp Ther; 2009 Jul; 330(1):89-98. PubMed ID: 19380603 [TBL] [Abstract][Full Text] [Related]
37. Comparison of oxidative damage in Malaysian end-stage renal disease patients with or without non-insulin-dependent diabetes mellitus. Kuppusamy UR; Indran M; Ahmad T; Wong SW; Tan SY; Mahmood AA Clin Chim Acta; 2005 Jan; 351(1-2):197-201. PubMed ID: 15563890 [TBL] [Abstract][Full Text] [Related]
38. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Rong LL; Gooch C; Szabolcs M; Herold KC; Lalla E; Hays AP; Yan SF; Yan SS; Schmidt AM Restor Neurol Neurosci; 2005; 23(5-6):355-65. PubMed ID: 16477098 [TBL] [Abstract][Full Text] [Related]
39. A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients. Kalousová M; Germanová A; Jáchymová M; Mestek O; Tesar V; Zima T Ann N Y Acad Sci; 2008 Apr; 1126():268-71. PubMed ID: 18079478 [TBL] [Abstract][Full Text] [Related]
40. AGE, RAGE, and ROS in diabetic nephropathy. Tan AL; Forbes JM; Cooper ME Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]